ClinicalTrials.Veeva

Menu
E

E-DA HealthCare Group | E-DA Cancer Hospital

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

ABBV-400
Ropeginterferon Alfa-2b
Erdafitinib
Docetaxel
Livmoniplimab
Hydroxyurea
Sacituzumab
LY3537021
P1101
Telisotuzumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

9 of 10 total trials

A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations (RAGNAR)

The purpose of this study is to evaluate the efficacy of erdafitinib in terms of overall response rate (ORR) in adult and pediatric participants with...

Active, not recruiting
Advanced Solid Tumor
Drug: Erdafitinib

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor,...

Enrolling
Non Small Cell Lung Cancer
Drug: Docetaxel
Biological: Telisotuzumab Vedotin

The purpose of this study is to compare the effectiveness of iberdomide maintenance to lenalidomide maintenance therapy after autologous stem cell tr...

Enrolling
Multiple Myeloma
Drug: Lenalidomide
Drug: Iberdomide
Locations recently updated

The purpose of this study is to check how well LY35327021 works and how safe it is for controlling nausea and vomiting caused by chemotherapy. Partic...

Begins enrollment this month
Vomiting
Nausea
Drug: Background Chemotherapy
Drug: Standard of Care Antiemetic Therapies

This is a Phase 3 open-label, multicenter, randomized, active-controlled study designed to compare the efficacy and safety and tolerability of P1101...

Active, not recruiting
Essential Thrombocythemia
Drug: Anagrelide
Biological: Ropeginterferon alfa-2b

This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or re...

Enrolling
Solid Tumor
Melanoma
Drug: Pemetrexed 500 mg/m2
Drug: Cisplatin 75mg/m2

The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) versus treatment of phy...

Active, not recruiting
Triple Negative Breast Cancer
PD-L1 Negative
Drug: Sacituzumab Govitecan-hziy
Drug: Paclitaxel

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events...

Enrolling
Platinum Resistant High Grade Epithelial Ovarian Cancer
Hepatocellular Carcinoma
Drug: Itraconazole (ITZ)
Drug: ABBV-400

Hepatocellular carcinoma (HCC) is a common cancer worldwide and a leading cause of cancer-related death. The majority of participants first presentin...

Active, not recruiting
Hepatocellular Carcinoma
Drug: Sorafenib
Drug: Livmoniplimab

Trial sponsors

AbbVie logo
Bristol-Myers Squibb (BMS) logo
Gilead Sciences logo
Janssen (J&J Innovative Medicine) logo
Lilly logo
P
P
I

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems